Check out our free and informative ezines and sign up now
The U.S. Patent Office issued the ’711 patent to Indian drugmaker Suven that covers the class of selective Serotonin receptor affinity compounds.
The compounds help treat neurodegenerative disorders, including Alzheimer’s, Parkinson’s disease, schizophrenia and Huntington’s disease.
Suven said this is its first U.S. patent. It has patent applications in the pipeline in several countries and anticipates they will be granted shortly.
ePublishing :: CMS, Hosting & Web Development | © Copyright